Your browser doesn't support javascript.
loading
Potential predictive value of serum targeted metabolites and concurrently mutated genes for EGFR-TKI therapeutic efficacy in lung adenocarcinoma patients with EGFR sensitizing mutations.
Han, Xiaohong; Luo, Rongrong; Wang, Lin; Zhang, Lei; Wang, Tao; Zhao, Yan; Xiao, Shanshan; Qiao, Nan; Xu, Chi; Ding, Lieming; Zhang, Zhishang; Shi, Yuankai.
Afiliação
  • Han X; Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs No. 41 Damucang Hutong, Xicheng District, Beijing 100032, China.
  • Luo R; Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs No. 17 Panjiayuan Nanli, Cha
  • Wang L; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China.
  • Zhang L; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs No. 17 Panjiayuan Nanli, Chaoya
  • Wang T; Hangzhou Repugene Technology CO., Ltd Hangzhou 311100, China.
  • Zhao Y; Beijing OMICS Biotechnology CO., Ltd Beijing 100094, China.
  • Xiao S; Hangzhou Repugene Technology CO., Ltd Hangzhou 311100, China.
  • Qiao N; Laboratory of Health Intelligence, Huawei Technologies Co., Ltd Shenzhen 518129, China.
  • Xu C; Laboratory of Health Intelligence, Huawei Technologies Co., Ltd Shenzhen 518129, China.
  • Ding L; Betta Pharmaceuticals Co., Ltd Hangzhou 311100, China.
  • Zhang Z; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs No. 17 Panjiayuan Nanli, Chaoya
  • Shi Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs No. 17 Panjiayuan Nanli, Chaoya
Am J Cancer Res ; 10(12): 4266-4286, 2020.
Article em En | MEDLINE | ID: mdl-33414999
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article